# Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis

> **NCT06720233** · PHASE3 · COMPLETED · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 37 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** SAL-0951 tablets

## Key facts

- **NCT ID:** NCT06720233
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02-22
- **Primary completion:** 2024-10-18
- **Final completion:** 2024-10-28
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06720233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06720233, "Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06720233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*